Limitations of the determination of faecal calprotectin in patients with ulcerative colitis and inflammatory polyps.

Limitaciones de la determinación de calprotectina fecal en pacientes con colitis ulcerosa y pólipos inflamatorios.

Journal

Gastroenterologia y hepatologia
ISSN: 0210-5705
Titre abrégé: Gastroenterol Hepatol
Pays: Spain
ID NLM: 8406671

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 31 05 2019
revised: 10 07 2019
accepted: 22 08 2019
pubmed: 28 10 2019
medline: 5 1 2021
entrez: 26 10 2019
Statut: ppublish

Résumé

Faecal calprotectin is a useful technique for detecting activity in patients with ulcerative colitis. However, there may be high levels due to factors other than the activity of ulcerative colitis. Our aim was to analyse possible false positive results of calprotectin for the activity of ulcerative colitis owing to the presence of inflammatory polyps. Retrospective, observational, descriptive study. Data was collected from patients monitored for 2 years in whom a colonoscopy had been requested within 3 months after detecting high calprotectin values (>150μg/g) and before modifying the treatment. We reviewed 39 patients and in 5 of them, with previous diagnosis of extensive ulcerative colitis, inflammatory polyps were detected. Three patients were on treatment with mesalazine, one with azathioprine and other with infliximab. All of them were asymptomatic and the endoscopy did not show macroscopic activity (endoscopic Mayo score=0) or histological activity. The median values of calprotectin were 422μg/g (IQR: 298-2,408) and they remained elevated in a second measurement. In 4 of the patients the inflammatory polyps were multiple and small in size. The other patient had a polyp measuring 4cm. In clinical practice we can find high faecal calprotectin levels not due to the presence of ulcerative colitis activity, but due to other lesions such as inflammatory polyps. This fact must be taken into account before carrying out relevant changes such as step-up therapy to immunosuppressive drugs or biological drugs in patients with confirmed high calprotectin levels.

Identifiants

pubmed: 31648810
pii: S0210-5705(19)30198-0
doi: 10.1016/j.gastrohep.2019.08.003
pii:
doi:

Substances chimiques

Leukocyte L1 Antigen Complex 0

Types de publication

Journal Article Observational Study

Langues

eng spa

Sous-ensembles de citation

IM

Pagination

73-78

Informations de copyright

Copyright © 2019 Elsevier España, S.L.U. All rights reserved.

Auteurs

Fernando Bermejo (F)

Servicio de Digestivo, Hospital Universitario de Fuenlabrada, Instituto de Investigación Sanitaria del Hospital Universitario La Paz (IdiPAZ), Madrid, España; Departamento de Medicina, Universidad Rey Juan Carlos, Madrid, España. Electronic address: fbermejos1@gmail.com.

Alicia Algaba (A)

Servicio de Digestivo, Hospital Universitario de Fuenlabrada, Instituto de Investigación Sanitaria del Hospital Universitario La Paz (IdiPAZ), Madrid, España.

Daniel Bonillo (D)

Servicio de Digestivo, Hospital Universitario de Fuenlabrada, Instituto de Investigación Sanitaria del Hospital Universitario La Paz (IdiPAZ), Madrid, España.

Laura Jiménez (L)

Servicio de Digestivo, Hospital Universitario de Fuenlabrada, Instituto de Investigación Sanitaria del Hospital Universitario La Paz (IdiPAZ), Madrid, España.

Antonio Guardiola-Arévalo (A)

Servicio de Digestivo, Hospital Universitario de Fuenlabrada, Instituto de Investigación Sanitaria del Hospital Universitario La Paz (IdiPAZ), Madrid, España.

María Pacheco (M)

Servicio de Laboratorio, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, España.

Ángel Castaño (Á)

Servicio de Anatomía Patológica, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, España.

Iván Guerra (I)

Servicio de Digestivo, Hospital Universitario de Fuenlabrada, Instituto de Investigación Sanitaria del Hospital Universitario La Paz (IdiPAZ), Madrid, España.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH